ONI Reader Poll Online

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 5
Volume 16
Issue 5

Last month, ONI launched a new interactive feature: an electronic Reader Poll located on The Oncology Group website

MANHASSET, New York—Last month, ONI launched a new interactive feature: an electronic Reader Poll located on The Oncology Group website (www.cancernetwork.com). The poll question is keyed to an important article in each month's print issue.

In April, the poll question (at right) asked about possible ways to prevent the predicted shortage of oncologists in 2020. Of the more than 100 readers who voted, 41% said the best tactic is to increase the number of oncology fellowships. Increasing the use of nonphysician clinicians came in second at 23%, offering incentives to delay retirement was next at 15%, expanding the primary care physician's role for patients in remission garnered 14% of the vote, and improving health information technology (HIT) systems (to reduce paperwork) came in last at 7%.

Recent Videos
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
4 KOLs are featured in this series.